✓ Translated by DotMD AI Clinical Council Source: American journal of obstetrics and gynecology • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #35863457 ↗

Phase III Randomized Trial: Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections (N = 219)

Original Paper Title: “Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 219
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • In participants with recurrent vulvovaginal candidiasis, oteseconazole was safe and efficacious in the treatment and prevention of recurrent acute vulvovaginal candidiasis episodes and was noninferior to vulvovaginal candidiasis standard-of-care fluconazole in the treatment of the presenting acute vulvovaginal candidiasis infection.
  • Study Design & Sample: Phase III Randomized Trial published in American journal of obstetrics and gynecology (N = 219 human participants).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in American journal of obstetrics and gynecology (2022), this phase iii randomized trial evaluating 219 human participants investigated: Recurrent vulvovaginal candidiasis affects nearly 138 million women globally each year. Key clinical takeaway: In participants with recurrent vulvovaginal candidiasis, oteseconazole was safe and efficacious in the treatment and prevention of recurrent acute vulvovaginal candidiasis episodes and was noninferior to vulvovaginal candidiasis standard-of-care fluconazole in the treatment of the presenting acute vulvovaginal candidiasis infection.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (American journal of obstetrics and gynecology, 2022-12-15; N = 219; Rigor 88/100): In participants with recurrent vulvovaginal candidiasis, oteseconazole was safe and efficacious in the treatment and prevention of recurrent acute vulvovaginal candidiasis episodes and was noninferior to vulvovaginal candidiasis standard-of-care fluconazole in the treatment of the presenting acute vulvovaginal candidiasis infection.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: oteseconazole → Rx: fluconazole → Rx: silka-antifungal-terbinafine-hydrochloride → Rx: foot-cure-antifungal-foot-balm-zinc-undecylenate → Condition: louse-borne-relapsing-fever-lbrf → Condition: antibiotic-resistance →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 35863457: Phase III Randomized Trial: Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections (N = 219)

3 of 3 Free Questions Remaining